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Derangement in Serum Inflammatory Biomarkers Among Patients with End Stage Renal Disease 
 DR.  MUHAMMAD TAUQEER, MBBS NISHTAR HOSPITAL, MULTAN.  DR. SYED HASAN NABEEL, MBBS, MCPS NISHTAR HOSPITAL, MULTAN.  DR. SANA ASHRAF, MBBS NISHTAR HOSPITAL, MULTAN  Abstract Background: End stage renal disease is an important public health problem. Renal replacement therapy, dialysis and transplantation are used to provide relief from the symptoms of end stage renal disease whilst also preserving the life of the patients though they are not curative. Haemodialysis is the widely used method although it produces a negative impact on quality of life of the patients. Hypoalbumianemia has been reported to be frequently present in haemodialysis patients and correlates strongly with mortality and morbidity. Objective: To determine the frequency of deranged  inflammatory biomarkers in patients with end stage renal disease on hemodialysis, in Nishtar Hospital Multan. Material and methods: One hundred thirty-one cases with ESRD were selected from Hemodialysis Department, Nishtar Hospital Multan and  3ml of venous blood sample was taken before starting a session of hemodialysis and sent to central laboratory of Nishtar Hospital Multan. Serum Albumin was obtained by an automatic analyzer, and serum CRP by slide test, free of cost, to measure deranged inflammatory biomarkers. Data was analyzed by using SPSS version 20. Results: Of these 131 study cases, 85 (64.9%) were male patients while 46 (35.1%) were female patients. Mean age of our study cases was 42.37 ± 5.98 years. Of these 131 patients with ESRD on hemodialysis 33 (25.2%) were diabetic, 65 (49.6%) were hypertensives and 13 (9.9%) were obese. Mean duration on hemodialysis was 19.51 ± 7.59 months, 80 (61.1%) had to undergo hemodialysis twice a week and 51 (38.9%) had to undergo three times a week. Mean serum albumin level was noted to be 3.37 ± 0.59 g/dl. Mean serum C-reactive protein level was noted to be 20.73 ± 15.84 mg/l. Frequency of deranged inflammatory biomarkers in our study was noted to be in 109 (83.2%) of the study cases. Conclusion: Very high frequency of derangement in inflammatory biomarkers have been noted in our study. This derangement in these inflammatory biomarkers was significantly associated with female gender, increasing age, increased duration on hemodialysis and increased frequency of hemodialysis. The early diagnosis of these derangements followed by preventive measures can help decrease disease morbidity and mortality among targeted population.  Keywords: Inflammatory biomarkers, deranged, end-stage renal disease, hemodialysis.                                         Introduction: End stage renal disease (ESRD), a consequence of chronic kidney disease (CKD), includes patients treated  either by dialysis or transplantation, irrespective of the level of glomerular filtration rate (GFR)1. The number of patients with CKD and thus ESRD are increasing day by day and the problem is worldwide1. In Pakistan almost 15-20% of persons above 40 years of age are suffering from CKD2. Patients with chronic kidney disease (CKD) have an increased prevalence of inflammation as measured by any of a number of biomarkers3. These biomarkers are proteins whose plasma concentrations increases or decreases in response to inflammation. The causes of inflammation are multifactorial and include underlying disease, comorbidity, oxidative stress, infections, obesity, and genetic or immunologic factors3. The hemodialysis related factors depend on  membrane biocompatibility and dialysate quality3.In one study, between 30 and 50% of  prevalent patients who were on hemodialysis (HD) had elevated serum levels of inflammatory biomarkers3. These markers can be used for the prediction of future cardiovascular events 4. Cardiac diseases are one of the main causes of mortality and morbidity in ESRD patients1. Different studies showed that cumulative risk of cardiac disease is approximately 20%, in patients with renal disease, which is almost equivalent to the risk seen in patients who are suffering from previous cardiovascular disease1. Chronic inflammation is a risk factor for cardiovascular disease among HD patients and contributes to the excess cardiovascular morbidity and mortality5.  Among several novel risk factors, inflammation has attracted considerable interest in the last 10 years6. Serum Albumin and C reactive protein are two important inflammatory biomarkers. HEMO study found that both CRP and albumin were independent 
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predictors of all-cause mortality in HD patients7. Serum Albumin concentration decreases in dialysis patients primarily as a consequence of increased inflammation with a subsequent decline in the rate of albumin synthesis8. Hypoalbuminemia is a strong and independent predictor of mortality9. Serum albumin, predicts mortality in HD patients, particularly when <3.8 g/dL10. A similar study conducted in Pakistan showed that 90.6% of 64  hemodialysis patients had serum albumin <4g/dL11.C reactive protein was >10 mg/L in 39.5% patients11. C reactive protein is a protein produced in the liver. CRP level is an independent predictor for all-cause mortality in HD patients 12. In one study, after exclusion of those with a clinically apparent infection, 29.3% of HD patients had increased CRP levels13. CRP is a prominent product of the inflammatory response syndrome and a marker of overall and cardiovascular death in the general population as well as in HD patients. A successful treatment of the underlying inflammatory conditions will improve long-term survival7. By emphasizing on screening of inflammatory biomarkers in ESRD, causes of inflammation in patients with these biomarkers, can be determined through clinical investigation and can be eliminated or corrected. A successful treatment of the inflammatory conditions and thus modification of risk factors of cardiovascular outcome, will reduce mortality among patients on HD14, 15.  Materials and Methods: One hundred thirty-one cases with ESRD were selected from Hemodialysis Department, Nishtar Hospital Multan. Patients with acute renal failure having S. Creatinine  levels more than 1.2 mg/dL, for less than 3 months, patients with any pre existing acute infection having  Neutrophils  > 75%, patients with pre-existing malignant tumors and patients with history of any surgical procedure in last 10 days were excluded. After detailed history, examination and record review, anthropometric measures like weight and height were measured by a standardized weight scale and a standardized height measuring tape respectively. Deranged Inflammatory Biomarkers was defined as Presence of any one of following was labelled as a deranged inflammatory biomarker. Serum Albumin < 4 g/dL, Serum C reactive protein > 10 mg/L.End Stage Renal Disease was defined as Patients with GFR < 15 ml/min and on hemodialysis for the last 3 months or greater  than that. GFR estimated by Cockroft-Gault Formula i.e for male:           (140-Age)×Weight(Kg) / 72×S.Creatinine (mg/dL) for female:        (140-Age)×Weight(Kg)×0.85 / 72×S.Creatinine (mg/dL).   3ml of venous blood sample was taken before starting a session of hemodialysis and sent to central laboratory of Nishtar Hospital Multan. Serum Albumin was obtained by an automatic analyzer, and serum CRP by slide test, free of cost, to measure deranged inflammatory biomarkers. Data was analyzed by using SPSS version 20. Descriptive statistics was applied to calculate mean and standard deviation of age, S. Albumin and serum CRP of participants. Frequencies  and percentages were calculated for qualitative variables like gender, age groups, Diabetes Mellitus (Yes/No), Hypertension (Yes/No), deranged  inflammatory biomarkers (Yes/No)  in hemodialysis patients.   Results: Our study included a total of 131 patients with end stage renal disease (ESRD) meeting inclusion and exclusion criteria of this study. Of these 131 study cases, 85 (64.9%) were male patients while 46 (35.1%) were female patients. Mean age of our study cases was 42.37 ± 5.98 years ranging from 29 years to 50 years and 105 (80.2%) were having their ages ranging from 36 – 50 years of age. Of these 131 patients with ESRD on hemodialysis 33 (25.2%) were diabetic, 65 (49.6%) were hypertensives and 13 (9.9%) were obese. Mean duration on hemodialysis was 19.51 ± 7.59 months ranging from 10 months to 36 months while 79 (60.3%) were having duration up to 18 months, while 80 (61.1%) had to undergo hemodialysis twice a week and 51 (38.9%) had to undergo three times a week. Mean serum albumin level was noted to be 3.37 ± 0.59 g/dl ranging from 2.5 g/dl to 4.5 g/dl. Mean serum C-reactive protein level was noted to be 20.73 ± 15.84 mg/l (with minimum level of serum C-reactive protein was 6 while maximum level was 48 mg/l). Frequency of deranged inflammatory biomarkers in our study was noted to be in 109 (83.2%) of the study cases. This derangement of inflammatory biomarkers was stratified with regards to gender, age, diabetes, hypertension, obesity, duration on hemodialysis and frequency of hemodialysis and p values were found to be p=0.000, p=0.075, p=0.430, p=0.124 , p=0.168, p=0.000 and p=0.000, respectively.  
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Table No. 1  Stratification of deranged inflammatory biomarkers with regards to gender.  Gender Deranged inflammatory biomarkers  P – value  Yes (n=109) No (n=22) Male (n=85) 63 22   0.000 Female (n=46) 46 00 Total 131  Table No. 2 Stratification of deranged inflammatory biomarkers with regards to age.  Age groups Deranged inflammatory biomarkers  P – value  Yes (n=109) No (n=22) 20 – 35 Years (n=26) 25 01    0.075 36 – 50 Years (n=105) 84 21  Total  131  Table No. 3 Stratification of deranged inflammatory biomarkers with regards to diabetes. (n=131)  Diabetes Deranged inflammatory biomarkers  P – value  Yes (n=109) No (n=22) Yes (n=33) 26 07   0.430 Yes (n=98) 83 15 Total 131  Table No. 4 Stratification of deranged inflammatory biomarkers with regards to hypertension.  Hypertension Deranged inflammatory biomarkers  P – value  Yes (n=109) No (n=22) Yes (n=65) 51 14    0.168 Yes (n=66) 58 08  Total  131  Table No. 5 Stratification of deranged inflammatory biomarkers with regards to duration on hemodialysis.  Duration  Deranged inflammatory biomarkers  P – value  Yes (n=109) No (n=22) Equal/Less than 18 months (n=79) 57 22    0.000 More than 18 months (n=52) 52 00  Total  131  
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Table No. 6 Stratification of deranged inflammatory biomarkers with regards to frequency of hemodialysis.  Frequency Deranged inflammatory biomarkers  P – value  Yes (n=109) No (n=22) Twice a week (n=80) 59 21   0.000 Thrice a week (n=51) 50 01  Total  131  Discussion: Our study included a total of 131 patients with end stage renal disease (ESRD) meeting inclusion and exclusion criteria of this study. End stage renal disease has been documented to be more prevalent in male patients, similarly of these 131 study cases, 85 (64.9%) were male patients while 46 (35.1%) were female patients. Siddiqui et al 11 reported 67 % male gender predominance which is in consistent with that of our study results. A study conducted by Iftikhar et al 16 from Lahore has reported 58 % male gender predominance, which is in compliance with that of our study findings. A study from Saudi Arabia 17 has also reported male gender predominance in 61 % male patients, which is similar to that of our study results. Machingura et al 18 from Zimbabwe has reported male gender predominance in 70 % patients with ESRD on hemodialysis, these findings are close to that of our study results. Menon et al 19 also reported 58 % male gender predominance which is close to our study results.  Mean age of our study cases was 42.37 ± 5.98 years (with minimum age was 29 years while maximum age was 50 years). Our study results have further indicated that majority of our study cases i.e. 105 (80.2%) were having their ages ranging from 36 – 50 years of age. Siddiqui et al from Rawalpindi 11 has reported 44.5 ±  14.3 years mean age of ESRD patients on hemodialysis. A study conducted in Lahore by Anees et al 20 has reported 46.10 ± 16.29 years mean age of patients on hemodilaysis, these findings are close to that of our study results. Machingura et al 18 reported 46.7 ± 13.5 years mean age of these patients of ESRD on hemodialysis, these findings are close to that of our study results. Of these 131 patients with ESRD on hemodialysis 33 (25.2%) were diabetic, 65 (49.6%) were hypertensives and 13 (9.9%) were obese. Anees et al 20 reported similar findings.  Mean duration on hemodialysis was 19.51 ± 7.59 months (with minimum duration on hemodialysis was 10 months while maximum duration was 36 months). Our study results have reported that majority of our study cases i.e. 79 (60.3%) were having duration up to 18 months. Anees et al 20 reported mean duration on hemodialysis to be 24.87 ± 22.1 months which is similar to that of our findings.  While 80 (61.1%) had to undergo hemodialysis twice a week and 51 (38.9%) had to undergo three times a week. Anees et al also reported majority of the patients 40 (74.1%) were on twice weekly dialysis. These findings of Anees et al 20 are similar to that of our study results. Mean serum albumin level was noted to be 3.37 ± 0.59 g/dl (with minimum serum albumin level was 2.5 and maximum serum albumin level was 4.5 g/dl). Machingura et al 18 reported mean serum albumin level to be 3.36 ± 0.61 g/dl which is similar to that of study results.  Menon et al 19 reported 4.0 ± 0.4 g/dl mean serum albumin level which is close to our study results. Siddiqi et al 11 reported 3.4 ± 0.4 mean value of serum albumin level which is close to that of our study results. Mean serum C-reactive protein level was noted to be 20.73 ± 15.84 mg/l (with minimum level of serum C-reactive protein was 6 while maximum level was 48 mg/l). Menon et al 19 reported 1 – 73 mg/liter range of CRP in these patients.  Frequency of deranged inflammatory biomarkers in our study was noted to be in 109 (83.2%) of the study cases. Machingura et al 18 from Zimbabwe has reported 70.4 % derangement in inflammatory biomarkers (hypoalbuminemia), which is close to our study results. Siddiqui et al 11 from Rawalpindi reported 90.6 % frequency of derangement in inflammatory biomarkers, which is close to our study results. Menon et al 19 also reported similar results and documented these inflammatory biomarkers were independently associated with mortality in these patients with ESRD.   Conclusion: Very high frequency of derangement in inflammatory biomarkers have been noted in our study. This derangement in these inflammatory biomarkers was significantly associated with female gender, increasing age, increased duration on hemodialysis and increased frequency of hemodialysis. The early diagnosis of these 
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